These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 4044020)
1. Effect of melphalan administration on the activity of natural killer and natural cytotoxic spleen cells of normal and tumor-bearing mice. Nahas F; Ophir R; Ben-Efraim S Immunol Lett; 1985; 10(6):333-7. PubMed ID: 4044020 [TBL] [Abstract][Full Text] [Related]
2. Melphalan-induced appearance of potent antitumor immune reactivity in tumor bearer lymphocytes co-expressing the Lyt 2 and the L3T4 antigens. Takesue BY; Bartik MM; Mokyr MB Int J Immunopharmacol; 1987; 9(6):705-17. PubMed ID: 2891627 [TBL] [Abstract][Full Text] [Related]
3. Melphalan-induced enhancement of antitumor immune reactivity in thymocytes of adult BALB/c mice bearing a large MOPC-315 tumor. Bartik MM; Takesue BY; Mokyr MB Cancer Res; 1987 Sep; 47(18):4848-55. PubMed ID: 3497711 [TBL] [Abstract][Full Text] [Related]
4. Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor. Gorelik L; Rubin M; Prokhorova A; Mokyr MB J Immunol; 1995 Apr; 154(8):3941-51. PubMed ID: 7706732 [TBL] [Abstract][Full Text] [Related]
5. Phorbol ester-induced enhancement in lytic activity of CD8+ splenic T cells from low-dose melphalan-treated MOPC-315-tumor bearers. Weiskirch LM; Baumgartel BA; Barker E; Mokyr MB Cancer Immunol Immunother; 1991; 32(6):353-63. PubMed ID: 1901031 [TBL] [Abstract][Full Text] [Related]
6. The difference between 5-fluorouracil and melphalan in their ability to promote antitumor immune response against MOPC-315 plasmacytoma. Ben-Efraim S; Shoval S; Ophir R Cancer Immunol Immunother; 1986; 22(1):43-8. PubMed ID: 2939947 [TBL] [Abstract][Full Text] [Related]
7. Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers. Barker E; Wise JA; Dray S; Mokyr MB Cancer Res; 1989 Sep; 49(18):5007-15. PubMed ID: 2788494 [TBL] [Abstract][Full Text] [Related]
8. Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers. Mokyr MB; Barker E Cancer Immunol Immunother; 1986; 23(1):11-9. PubMed ID: 3490305 [TBL] [Abstract][Full Text] [Related]
9. Some approaches to improve the therapeutic effectiveness of adoptive chemoimmunotherapy with spleen cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor. Weiskirch LM; Mokyr MB Int J Cancer; 1992 Apr; 51(1):84-92. PubMed ID: 1563847 [TBL] [Abstract][Full Text] [Related]
10. Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor. Gorelik L; Prokhorova A; Mokyr MB Cancer Immunol Immunother; 1994 Aug; 39(2):117-26. PubMed ID: 8044831 [TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy. Weiskirch LM; Bar-Dagan Y; Mokyr MB Cancer Immunol Immunother; 1994 Apr; 38(4):215-24. PubMed ID: 8168116 [TBL] [Abstract][Full Text] [Related]
12. Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells. Barker E; Mokyr MB Cancer Res; 1988 Sep; 48(17):4834-42. PubMed ID: 3261626 [TBL] [Abstract][Full Text] [Related]
13. Importance of Lyt 2+ T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor. Mokyr MB; Barker E; Weiskirch LM; Takesue BY; Pyle JM Cancer Res; 1989 Aug; 49(16):4597-606. PubMed ID: 2568174 [TBL] [Abstract][Full Text] [Related]
14. Involvement of TCR-V beta 8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan. Mokyr MB; Rubin M; Newell KA; Prokhorova A; Bluestone JA J Immunol; 1993 Nov; 151(9):4838-46. PubMed ID: 8409442 [TBL] [Abstract][Full Text] [Related]
15. Melphalan-induced enhancement of tumor cell immunostimulatory capacity as a mechanism for the appearance of potent antitumor immunity in the spleen of mice bearing a large metastatic MOPC-315 tumor. Bocian RC; Dray S; Ben-Efraim S; Mokyr MB Cancer Immunol Immunother; 1985; 20(1):61-8. PubMed ID: 3933817 [TBL] [Abstract][Full Text] [Related]
16. Interleukin 2 requirement for the in vitro generation of antitumor cytotoxicity by thymocytes from melphalan-cured MOPC-315 tumor bearers. Mokyr MB; Bartik MM; Ahn MC Cancer Res; 1989 Feb; 49(4):870-6. PubMed ID: 2783557 [TBL] [Abstract][Full Text] [Related]
17. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. II. Enhancement of in vitro cell-mediated cytotoxicity by combined chemotherapy-immunotherapy. Adler A; Keisari Y; Ofir R J Natl Cancer Inst; 1985 Feb; 74(2):429-36. PubMed ID: 3856051 [TBL] [Abstract][Full Text] [Related]
18. Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor. Weiskirch LM; Barker E; Mokyr MB Cancer Immunol Immunother; 1990; 31(3):129-38. PubMed ID: 2337902 [TBL] [Abstract][Full Text] [Related]
19. Neurotransmitter suppression of the in vitro generation of a cytotoxic T lymphocyte response against the syngeneic MOPC-315 plasmacytoma. Cook-Mills JM; Mokyr MB; Cohen RL; Perlman RL; Chambers DA Cancer Immunol Immunother; 1995 Feb; 40(2):79-87. PubMed ID: 7882386 [TBL] [Abstract][Full Text] [Related]
20. Presence of an enlarged pool of MOPC-315-specific cytotoxic T lymphocyte precursors in the thymuses of mice that eradicated a large MOPC-315 tumor as a consequence of low-dose melphalan therapy. Bartik MM; Ahn MC; Baumgartel BA; Hendricks RL; Mokyr MB Cancer Immunol Immunother; 1990; 32(3):143-53. PubMed ID: 2289208 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]